CoChat

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Open access

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1302507

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 2,324

Metadata

Authors
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
Affiliations
  • University of Perugia (IT)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • King's College Hospital (GB)
  • Pfizer (United States) (US)
  • Flinders University (AU)
  • University of Oklahoma Health Sciences Center (US)
  • Thrombosis and Atherosclerosis Research Institute (CA)
Venue
New England Journal of Medicine
Published
2013-08-29
Volume
369
Issue
9
Pages
799-808
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2166402206
Cited by
2,324
References
13
Citations by year
2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
FWCI
194.63
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
MeSH terms
Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.